Genomic Database To Aid Treatment Of Rare Diseases

25 Nov 2019 | 04.55 pm

Genomic Database To Aid Treatment Of Rare Diseases

Open Orphan signs up pharma and biotech firms

25 Nov 2019 | 04.55 pm

Five pharma and biotech companies have signed up as early adopters of a genomic health database being developed by Open Orphan, the rare and orphan drug consulting company.

Open Orphan’s Genomic Health DataBANK platform is expected to go live in the first quarter of 2020, and recruiting the five companies “will ensure the database is ‘fit-for-purpose’ from a pharmaceutical and data analysis perspective ahead of the first patient data upload”, according to the company.

The plc recently agreed a deal with NovaUCD spinoff Empiric Logic to complete the build out of Open Orphan’s data platform, which it says will be Europe’s first rare disease, advocacy-led genomic database. The strategic agreement provides for the incorporation of Empiric Logic’s privacy preserving, artificial intelligence-enabled software into Open Orphan’s platform, to aid the collection and management capabilities of the software.

Open Orphan CEO Cathal Friel (pictured) stated: “We are very excited to be working with these leading pharmaceutical and biotechnology companies on our market leading DataBANK, which will launch in early 2020. We believe the DataBANK can ignite research for new diagnostic tools and therapeutic products for rare disease patients.”

A key objective of the databank is to empower patients to directly drive research into their own particular disease, and to further this Open Orphan is in talks to finalise early adopter agreements with patient advocacy groups that will make their members aware of the new platform.

Open Orphan is also developing its Virtual Rep platform that enables pharmaceutical companies to engage key opinion leaders and physicians. Friel added that the company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry, targeting under-supplied treatment for life-threatening or very serious diseases and rare disorders.

Comments are closed.